Go Back
00:04:43
00:11:01
00:04:37
00:15:54
00:06:14
00:06:46
00:10:03
00:05:40
00:06:25
00:07:49
00:13:46
00:16:43
00:16:16
00:07:46
00:10:31
00:06:15
00:06:41
00:12:56
Latest Videos
Teresa Klinowska, Ph.D. @AstraZeneca #SABCS20 #BreastCancer #Cancer #Research SERENA-1 Phase I trial
Michele Ghidini, MD @michele_ghidini @ASSTCremona @policlinicoMI #ASCOGI #gastriccancer #gastrointestinalcancer #cancer #research Post-hoc analyses of the phase III tags trial
Aung Naing, MD @ANaingMD @MDAndersonNews #advancedrarecancers #Cancer #Research Phase 2 study of pembrolizumab in patients with advanced rare cancers
Omar M. Abdelsalam, MD @omarabdelrhman @UAlberta_FoMD #ColorectalCancer #BreastCancer #CervicalCancer #Cancer #Research Dangerous Disparities for Life-Saving Cancer Screening
Afsaneh Barzi, MD @Dr_AfsanehBarzi @cityofhope #ASCOGI20 #ColorectalCancer #Cancer #Research Disparities in Access to Screening and Variation of Targets in Different Groups
Afsaneh Barzi, MD @Dr_AfsanehBarzi @cityofhope #ASCOGI20 #ColorectalCancer #Cancer #Research Health-related quality of life and time from diagnosis among young adult colorectal cancer sur...
Helene Rundqvist @HHeleneru @karolinskainst #BreastCancer #Cancer #Research Cytotoxic T-cells mediate exercise-induced reductions in tumor growth
Larysa Sanchez, MD @IcahnMountSinai @TischCancer #ASH20 #MultipleMyeloma #Cancer #Research Real-World Treatment Patterns and Outcomes of Proteasome Inhibitor
Antonio Llombart, MD @harnaulleida @wearemedsir #SABCS #BreastCancer #Cancer #Research PARSIFAL a Multicenter, Randomized, Open-Label, Phase II Trial
Antonio Llombart, MD @harnaulleida @wearemedsir #SABCS #BreastCancer #Cancer #Research BIOPER A Phase II Proof-of-Concept Study
Eunice S. Wang, MD @EuniceWangMD @RoswellPark #ASH20 #AML #Cancer #Research Phase 3, Multicenter, Open-Label Study of Gilteritinib, Gilteritinib Plus Azacitidine
Christina Peters, MD @StAnna_CCRI @KidsCancerInst #ChildhoodALL #ALL #Cancer #Research A Multinational, Randomized, Noninferiority Phase III Study on Childhood ALL
Prof. Dan Aderka @SHEBA_ #Virtual-GI20 #ColorectalCancer #Cancer #Research Optimal Sequence of Targeted Agents for All RAS & BRAF Patient Sub-types
Aung Naing, MD, FACP @ANaingMD @MDAndersonNews #adverseevents #Cancer #Research Strategies for improving the management of immune-related adverse events
Jorge Cortes, MD @GCC_Cortes @GACancerCenter #CML #Cancer #Research U.S. FDA Approves Supplemental New Drug For Pts with CML
Robert M. Rifkin, MD #RockyMountainCancerCenter #ASH20 #MultipleMyeloma #Cancer #Research DREAMM-7: A Phase III Study
Robert M. Rifkin, MD #RockyMountainCancerCenter #ASH20 #MultipleMyeloma #Cancer #Research The Phase 3 TOURMALINE-MM2 Trial
